Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Sucampo inks licensing agreement with Gloria
July 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

BETHESDA, Md.—Sucampo Pharmaceuticals Inc. and Harbin Gloria Pharmaceuticals Co. Ltd. (Gloria) have begun an exclusive license, development, commercialization and supply agreement for AMITIZA in the People’s Republic of China. Per the agreement, Gloria gains the rights to develop and commercial AMITIZA in China, subject to regulatory approval of the product by the China Food and Drug Administration. Gloria will pay Sucampo $1.5 million up front, as well as a milestone payment, and the agreement will span 13 years with renewal terms. Sucampo will be the exclusive supplier of AMITIZA to Gloria, and Gloria will be responsible for all development activities and costs.
 
“Current treatment options for constipation are not effective for all patients, and Gloria’s local expertise and established commercial infrastructure may provide the patient population in China with a new alternative. We are pleased to partner with Gloria to expand access to AMITIZA to even more patients,” said Sucampo CEO Peter Greenleaf.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.